Novartis, Takeda to enter next Medicare drug price negotiations

Endpoints NewsDimension seeks up to $750M for third life sciences fund after string of success

Endpoints NewsElevance talks 'practical' AI

Endpoints NewsMammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once again

FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2

Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug

CellPaleogenomes reveal the evolutionary relationship between modern and cave lions

Endpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cuts

Endpoints NewsSupreme Court sides with Hikma in 'skinny label' case

FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too

Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic

BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2B

FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3